| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADRb2 |
| Uniprot No | P07550 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 330-413aa |
| 氨基酸序列 | PDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL |
| 预测分子量 | 23.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADRb2(β2-肾上腺素受体)重组蛋白的3篇代表性文献摘要，供参考：
---
1. **文献名称**：*Crystal structure of the β2 adrenergic receptor–Gs protein complex*
**作者**：Rasmussen, S. G. et al.
**摘要**：该研究首次解析了ADRb2重组蛋白与激动剂(BI-167107)及Gs蛋白复合体的高分辨率晶体结构(3.0 Å)，揭示了受体激活后构象变化如何促进G蛋白偶联的信号转导机制，为理解GPCR功能提供结构基础。
2. **文献名称**：*Structure of a nanobody-stabilized active state of the β2 adrenoceptor*
**作者**：Ring, A. M. et al.
**摘要**：通过纳米抗体稳定ADRb2重组蛋白的活性构象，结合X射线晶体学技术，阐明受体在无G蛋白存在时的活化状态特征，揭示了跨膜螺旋的重新排列对信号传递的关键作用。
3. **文献名称**：*The effect of ligands on the thermal stability of β2-adrenergic receptor*
**作者**：Yao, X. et al.
**摘要**：研究利用差示扫描量热法(DSC)分析不同配体(激动剂/拮抗剂)对重组ADRb2蛋白热稳定性的影响，发现激动剂结合显著降低受体稳定性，提示构象动态变化与功能调控的关联。
---
以上文献均聚焦于ADRb2的结构生物学与功能机制，涉及重组蛋白在解析受体激活、信号传导及配体互作中的应用。如需具体DOI或发表年份，可进一步补充。
**Background of ADRb2 Recombinant Protein**
The **ADRB2 (β2-adrenergic receptor)** is a member of the G protein-coupled receptor (GPCR) family, primarily involved in mediating physiological responses to catecholamines like epinephrine and norepinephrine. It plays a critical role in regulating smooth muscle relaxation, bronchial dilation, and metabolic processes. Structurally, ADRB2 consists of seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus, facilitating signal transduction through Gs proteins to activate adenylate cyclase and increase cAMP levels.
**Recombinant ADRB2 protein** is engineered using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional receptor protein for research and therapeutic applications. This technology enables precise study of ADRB2's ligand-binding properties, conformational dynamics, and interactions with downstream signaling partners.
ADRB2 is a major target in treating respiratory disorders such as asthma and COPD, where agonists like albuterol bind to the receptor to induce bronchodilation. However, chronic agonist exposure can lead to receptor desensitization via phosphorylation and β-arrestin recruitment, a mechanism extensively studied using recombinant ADRB2. Additionally, genetic polymorphisms (e.g., Arg16Gly) influence drug responsiveness, driving pharmacogenomic research with recombinant variants.
In drug discovery, recombinant ADRB2 serves as a tool for high-throughput screening of biased agonists or allosteric modulators that aim to enhance therapeutic efficacy while minimizing side effects. Its structural elucidation via cryo-EM and X-ray crystallography, enabled by recombinant protein production, has revolutionized GPCR-targeted drug design. Overall, ADRB2 recombinant protein remains pivotal in advancing both basic research and clinical innovation.
×
